Aktiesnakken — Juni 2013
-
men jeg ser lige på kursudviklingen idag,
-
J&J udvider pipen med ekspress fart
-
ser vi endelig lidt effekt af patent cliff?
-
det er det jeg siger. heller tidlig fase end sen fase stoffer
-
priserne er bare højere. Uforståeligt nok
-
godt HexaBody er tidlig phase
-
De har jo også punget godt ud for både Ibrutinib og Daratumumab
-
The deal includes Aragons and
rogen receptor antagonist program, which
includes the companys lead product candidate--known as ARN-509--for prostate
cancer. The treatment is in Phase 2 development. Aragons other assets will be
spun off into a new company in which J&J wont have an ownership stake. -
ja GSK har også været aktive
-
aftale
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind